India, Feb. 3 -- MetropolisHealthcare has announced its collaboration with Roche Diagnostics India and Neighbouring Markets to introduce the self-sampling human papillomavirus (HPV) DNA test for cervical cancer screening.

The launch of this test aims to expand access to cervical cancer screening across India by addressing social and economic barriers, making early detection more convenient for women, including those in Tier 2, Tier 3, and Tier 4 towns.

Cervical cancer is preventable and yet, India contributes to 21% of the world's total cases of cervical cancer. Currently, it accounts for nearly 79,000 deaths among Indian women each year, which is roughly two thirds of diagnosed cases. This indicates late-stage intervention which can be...